DexCom Inc. (DXCM)
NASDAQ: DXCMHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DXCM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.58B
- P/E (TTM)
- 31.23
- Forward P/E
- 25.30
- EPS (TTM)
- $2.54
- Dividend yield
- None
- 52-week range
- 56.72 – 92.59
- Day range
- 78.75 – 81.58
- Volume / Avg
- 4.61M / 4.19M
- Beta
- —
- Shares outstanding
- 372.95M
52-week range
DXCM stock today
Shares of DexCom (DXCM) finished lower on Nov 20 at $79.32, a drop of 1.08% or $0.87 per share, versus the S&P 500's 3.70% decline. At this level, DXCM sits in the middle of its 52-week range of $56.72 to $92.59: 14.3% below the high, set on Aug 24, 2026 and 39.8% above the low. DXCM is up 19.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 31.7%.
At 31.2x trailing earnings, DexCom trades below the peer-group median of 62.1x. Its forward P/E of 25.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About DexCom
Company profileDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Jacob Steven Leach
- Headquarters
- San Diego, CA
- Employees
- 11,000
- IPO year
- 2005
- Website
- dexcom.com
Financial highlights
Full financialsIn fiscal 2025, DexCom generated $4.66 billion in revenue, up 15.6% from fiscal 2024, its 16th consecutive year of revenue growth. Net income was $836.3 million (+45.1% year over year), for a net margin of 17.9% versus a median of 14.3% in the prior 5 years. Gross margin was 60.1% (down from 60.5%) and operating margin 19.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B |
| Growth | +15.60% | +11.34% | +24.49% | +18.84% | +27.08% |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M | $216.90M |
| EPS (diluted) | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 |
Analyst forecast
ForecastConsensus (29 analysts)
strong_buy
Avg. price target
$98.58+24.28%
- Strong buy 4
- Buy 22
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.72 vs $0.66
- Surprise
- +9.09%
DXCM news
All DXCM news- DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision LoomsNasdaq
- DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Here's Why You Should Retain DexCom Stock in Your Portfolio for NowNasdaqDXCM, ISRG, WST, GKOS
- DexCom to Launch 15-Day G7 CGM System in Canada This NovemberNasdaqDXCM, ISRG, OPK, GMED
- DexCom, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- DexCom: Improving Patient Access Makes It A Long-Term BuySeeking Alpha
- Dexcom (DXCM) Q3 2026 Earnings Call TranscriptNasdaq
- DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins RiseNasdaqDXCM, MMSI, OPK, GMED
DexCom peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| WSTWest Pharmaceutical Services Inc. | 390.30 | -1.61% | $27.19B | vs DXCM |
| RMDResMed Inc. | 235.63 | -0.53% | $33.14B | vs DXCM |
| SOLVSolventum Corporation | 84.50 | -1.52% | $14.36B | vs DXCM |
| GKOSGlaukos Corporation | 237.31 | -0.33% | $14.05B | vs DXCM |
| BAXBaxter International Inc. | 25.39 | 0.00% | $13.14B | vs DXCM |
| PENPenumbra Inc. | 319.12 | -0.28% | $12.58B | vs DXCM |
| MDLNMedline Inc. Class A | 37.04 | -2.11% | $48.75B | vs DXCM |
| PODDInsulet Corporation | 133.17 | -2.96% | $9.24B | vs DXCM |
Indexes, lists and sector
Index membership
DexCom stock FAQ
What is DexCom's stock price today?
DXCM last traded at $79.32 as of Nov 20, 4:00 PM EST, down 1.08% on the day. Prices are delayed at least 15 minutes.
Does DexCom pay a dividend?
No. DexCom does not currently pay a regular cash dividend.
What is DXCM's P/E ratio?
DXCM trades at a trailing P/E ratio of 31.23 and a forward P/E of 25.30, compared with a median of 62.1 for its closest peers.
Is DexCom in the S&P 500?
Yes. DexCom (DXCM) is a constituent of the S&P 500 index.
Who is DexCom's CEO?
Mr. Jacob Steven Leach is the chief executive officer of DexCom Inc., which has about 11,000 employees.
Has DXCM ever split its stock?
Yes. The most recent DXCM stock split was a 4-for-1 split on Jun 13, 2022.
What is the DXCM 52-week high?
The 52-week high for DXCM is $92.59 and the 52-week low is $56.72. The stock is currently 14.3% below its high.